Alexion Inks $125M Deal In Investors' Suit Over Sales Tactics
Alexion shareholders asked a Connecticut federal judge to approve a $125 million settlement to end claims that the drugmaker caused a double-digit plunge in stock price after its allegedly illegal sales...To view the full article, register now.
Already a subscriber? Click here to view full article